Larimar Therapeutics, Inc. (NASDAQ:LRMR), with a market capitalization of $228 million, is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases, with its lead ...

Larimar Therapeutics, Inc. (NASDAQ:LRMR), a clinical-stage pharmaceutical company with a market capitalization of $221 ...

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on LRMR stock, giving a Buy rating on January 24.Invest with ...

HC Wainwright reissued their buy rating on shares of Larimar Therapeutics (NASDAQ:LRMR – Free Report) in a report issued on Friday morning,Benzinga reports. HC Wainwright currently has a $15.00 target ...

Adolescents receive a weight-based dose equivalent to the 50 mg adult dose Adolescents 12-17 years old who complete participation in the pharmacokinetic (PK) run-in study will be eligible to screen in ...

Larimar doses adolescents in nomlabofusp paediatric pharmacokinetic run-in study for patients with Friedreich’s ataxia: Bala Cynwyd, Pennsylvania Saturday, January 25, 2025, 15: ...

Larimar Therapeutics reports promising FXN level increases with 25 mg nomlabofusp, advancing towards dose escalation for Friedreich's Ataxia treatment.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Fintel reports that on January 29, 2025, Truist Securities initiated coverage of Larimar Therapeutics (NasdaqGM:LRMR) with a Buy recommendation. As of January 29, 2025, the average one-year price ...

Larimar Therapeutics, Inc. (NASDAQ:LRMR), with a market capitalization of $228 million, is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases ...

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and ...